Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Apotex Inc. v. H. Lundbeck A/S

Fasken
Reading Time 1 minute read Subscribe

Overview

Client

Lundbeck

Apotex Inc. v. H. Lundbeck A/S
Action instituted by Apotex seeking a declaration of invalidity of Canadian patent no. 1,339,452 covering escitalopram on the grounds of anticipation, obviousness, inutility and insufficient disclosure. During this case : Lundbkeck answered with a counterclaim in infringement of the patent; The action instituted by Apotex was dismissed; The Counterclaim was granted; Apotex was condemned to an accounting of profits; Apotex appeal was discontinued. Lundbeck was advised in these proceedings by a team from Fasken Martineau that included Marie Lafleur, Julie Desrosiers and Christian Leblanc. For more information, see 2013 FC 192.

Team

    Subscribe

    Receive email updates from our team

    Subscribe